Interested participants could seek out Dr. Steven Potkin at the University
of California, Irvine, for timing information.
Alvin J. Glasky, Ph.D., Chairman and Chief Executive Officer of
NeoTherapeutics, Inc., discussed the clinical development program for the
Company's lead drug Neotrofin(TM).
Within 60 days, NeoTherapeutics expects to begin Phase 2 clinical studies in
Parkinson's disease, spinal cord injury and a higher dose 12-week pivotal
study in Alzheimer's disease.
Dr. Glasky highlighted the mounting evidence supporting Neotrofin's
potential effects. This discussion centered on a Phase 2 clinical study by
Dr. Steven Potkin Department of Psychiatry, University of California,
Irvine.
In this study, patients with Alzheimer's disease receiving 500 and 1,000 mg
per day of Neotrofin showed statistically significant improvement in memory,
attention and judgement after two weeks of dosing. Dr. Glasky also
explained results from a study which showed that Neotrofin causes the
proliferation of stem cells in the brains of adult mice. Studies are
currently underway to see the extent to which Neotrofin causes these new
brain stem cells to mature into neurons.
